review Open AccessTop 1% cited

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

The Lancet Oncology · 2017 · Vol. 18(3) · pp. e143–e152

Lesley Seymour✉(Queen's University)Jan Bogaerts(European Organisation for Research and Treatment of Cancer)Andrea Perrone(Merck & Co., Inc., Rahway, NJ, USA (United States))Robert Ford(Clinical Research Consulting)Lawrence H. Schwartz(Columbia University Irving Medical Center)Sumithra J. Mandrekar(Mayo Clinic)Nancy U. Lin(Dana-Farber Cancer Institute)Saskia Litière(European Organisation for Research and Treatment of Cancer)Janet Dancey(Queen's University)Alice Chen(National Cancer Institute)F. Stephen Hodi(Dana-Farber Cancer Institute)Patrick Therasse(Servier (France))Otto S. Hoekstra(Amsterdam UMC Location VUmc)Lalitha Shankar(National Cancer Institute)Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)Marcus Ballinger(Ludwig Cancer Research)Caroline Caramella(Institut Gustave Roussy)Elisabeth G.E. de Vries(University Medical Center Groningen)

Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Lymphoma Diagnosis and TreatmentGuidelineClinical trialMedicineMedical physicsResponse Evaluation Criteria in Solid TumorsImmunotherapyCancerIntensive care medicineOncologyInternal medicine

Citations

2,334

FWCI

87.01

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by